2 citations
,
October 2023 in “Dermatology and therapy” This study conducted in Europe found that both physicians and patients generally agreed on the severity of alopecia areata, with higher physician-rated severity linked to increased patient-reported burdens such as anxiety, depression, and work impairment.
227 citations
,
April 2023 in “The Lancet” Ritlecitinib effectively treats alopecia areata and is well-tolerated.
37 citations
,
August 2022 in “Frontiers in pharmacology” This study found that oral JAK inhibitors are effective and generally well-tolerated for treating alopecia areata, but high recurrence rates after stopping treatment suggest the need for continuous use.
22 citations
,
November 2021 in “Dermatology and Therapy” This study found that the Alopecia Areata Patient Priority Outcomes questionnaire is a reliable and valid tool for measuring the severity and impact of hair loss in individuals with alopecia areata.
117 citations
,
July 2021 in “British Journal of Dermatology” This study reports that the incidence of alopecia areata is 0.26 per 1000 person-years in the UK, with higher rates among Asian ethnic groups, socially deprived populations, and urban residents.
24 citations
,
June 2021 in “Journal of the European Academy of Dermatology and Venereology” This review highlights current knowledge about quality of life assessment in alopecia areata, noting limited use of existing instruments and a need for further validation.
67 citations
,
March 2021 in “Dermatology and Therapy” This review discusses the substantial impact of alopecia areata on patients' health-related quality of life, highlighting issues such as personality changes, emotional and social difficulties, and a common occurrence of alexithymia, and emphasizes the need for more specific assessment tools.
11 citations
,
March 2021 in “Dermatology and therapy” This study developed the Alopecia Areata Patient Priority Outcome (AAPPO), a new tool designed to measure and capture the symptoms and impacts of alopecia areata that matter most to patients.
7 citations
,
January 2021 in “Dermatology and therapy” This study confirmed that the Alopecia Areata-Investigator Global Assessment and other clinical outcome assessments are valid and relevant measures of treatment success for alopecia areata patients in Japan, aligning with previous North American findings.
30 citations
,
September 2020 in “Journal of Patient-Reported Outcomes” This study found that alopecia areata significantly impacts emotional and psychological well-being, relationships, and lifestyles, highlighting the need for increased awareness and effective treatments.
46 citations
,
August 2019 in “Journal of the European Academy of Dermatology and Venereology” This study found that patients with alopecia areata reported worse quality of life and higher anxiety and depression levels compared to those with androgenetic alopecia and healthy controls.
95 citations
,
November 2018 in “Australasian journal of dermatology” This consensus statement outlines a treatment algorithm for alopecia areata, discussing when to consider systemic treatment and how to assess outcomes, without providing new clinical results.
95 citations
,
July 2016 in “Journal of The American Academy of Dermatology” This review concluded that patients with alopecia areata consistently show poor health-related quality of life scores, similar to those in other chronic skin diseases like atopic dermatitis and psoriasis.
128 citations
,
February 2016 in “British Journal of Dermatology” This study found that patients with alopecia areata experience significant impairments in health-related quality of life, notably affecting mental health, according to various quality of life assessment tools.
25 citations
,
December 2015 in “Journal of the European Academy of Dermatology and Venereology” This study found that alopecia areata negatively affects patients' quality of life, though less severely than psoriasis, atopic dermatitis, and onychomycosis.
144 citations
,
July 2015 in “Clinical, Cosmetic and Investigational Dermatology” This review reports that alopecia areata affects about 2% of people globally and is linked with psychiatric and medical comorbidities, highlighting its significant disease burden.
45 citations
,
January 2013 in “Dermatology Research and Practice” This study found that patients with alopecia areata experience significantly poorer quality of life compared to the general population, affecting mental health, social functioning, and overall health outcomes.
218 citations
,
April 2012 in “British Journal of Dermatology” This updated guideline from the British Association of Dermatologists discusses current recommendations for managing alopecia areata but reports no new clinical research findings.
